Story · Medicine & Biotech
Jia Liu: The Lesson from Ivonescimab CRL on Designing Trials for Global Regulatory Approval
1 outlet · first reported by OncoDaily on
Jia Liu, Medical oncologist at The Kinghorn Cancer Centre, shared on X: “The ivonescimab FDA letter raises important questions extending beyond PFS versus OS. Despite approximately 40% of patients being enrolled (OncoDaily)
Coverage, in order
-
Jia Liu: The Lesson from Ivonescimab CRL on Designing Trials for Global Regulatory ApprovalJia Liu, Medical oncologist at The Kinghorn Cancer Centre, shared on X: “The ivonescimab FDA letter raises important questions extending beyond PFS versus OS. Despite approximately 40% of patients being enrolled
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.